

HR 1375

EFFECTIVE Act

Congress: 118 (2023–2025, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 3, 2023

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Mar 10, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/house-bill/1375>

Sponsor

Name: Rep. Trone, David J. [D-MD-6]

Party: Democratic • **State:** MD • **Chamber:** House

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Meuser, Daniel [R-PA-9]	R · PA		Mar 3, 2023
Rep. Kuster, Ann M. [D-NH-2]	D · NH		Mar 23, 2023
Rep. Kildee, Daniel T. [D-MI-8]	D · MI		Mar 27, 2023
Rep. Harder, Josh [D-CA-9]	D · CA		Apr 13, 2023
Rep. Pettersen, Brittany [D-CO-7]	D · CO		Jun 20, 2023

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 10, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 S 607	Identical bill	Mar 1, 2023: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Mar 3, 2023)

Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act or the EFFECTIVE Act

This bill specifies that the Food and Drug Administration may deny an application for a new opioid analgesic drug (i.e., opioid medication) upon a determination that the drug does not provide a significant advantage with respect to safety or effectiveness as compared to other drugs.

Actions Timeline

- **Mar 10, 2023:** Referred to the Subcommittee on Health.
- **Mar 3, 2023:** Introduced in House
- **Mar 3, 2023:** Referred to the House Committee on Energy and Commerce.